In multiple myeloma (MM) circulating CD19
Multiple myeloma is a B cell malignancy characterized by the accumulation of clonal plasma cells in the bone marrow secreting monoclonal immunoglobulins. Although the predominant malignant cell type in MM is the plasma cell, the initial oncogenic events are considered to take place in less mature B cell stages. 1 Several groups have provided evidence of peripheral blood B cell involvement by the myeloma clone using molecular biological tools [2] [3] [4] or flow cytometry techniques. [5] [6] [7] Furthermore, it has been reported that cytokines induce the differentiation of peripheral blood mononuclear cells obtained from patients with MM into plasma cells. 8, 9 The number and phenotype of these B cellrelated cells, as well as their role in the malignant process are still a matter of debate. 7, 10 Further resolution of these questions is necessary as a basis for the development of new treatment strategies, since despite treatment intensification most patients ultimately relapse.
The circulating clonotypic CD19 ϩ B cell is considered to be the source of progression after conventional treatment due to the expression of the multidrug resistance complex. 11 Furthermore, Billadeau et al. 12 reported that the number of malignant cells in PB remains fairly stable during the course of high-dose treatment. We addressed the question of fate of tumor cells in the CD19 ϩ B cell compartment during high-dose treatment by comparing tumor cell numbers in samples from patients after conventional chemotherapy with those after HDT. After HDT we distinguished two patients groups: patients in remission and patients who developed progressive disease. The proportion of malignant cells in PB samples was determined using a quantitative PCR assay based on limiting dilutions with allele-specific oligonucleotides (ASO) derived from the complementarity determining region 3 (CDR3). The number of CD19 ϩ as well as CD19
Ϫ tumor cells was assessed. Additionally, the tumor cell content in CD20 ϩ cell fractions (CD20 as marker coexpressed with CD19 on mature B cells) was determined to confirm the results obtained in the CD19 ϩ fractions.
Materials and methods

Patient samples
Twenty-five PB samples from 22 patients were used in the study. Eight samples were collected after treatment of the patients with VA[I]D (vincristine, adriamycin, (idarubicin), dexamethasone) immediately prior to the start of mobilization therapy. At that time, one patient was in complete remission (CR), five patients had achieved partial remission (PR) and two patients showed minimal response (MR) according to the EBMT criteria. 13 Post-HDT, 10 samples were assessed from patients who had achieved remission. Four of these patients were in CR and six had achieved PR. A further seven samples were collected when patients had developed progressive disease post-transplantation. Samples were collected prior to and post-HDT with PBSCT from one patient. Samples from a further two patients were analyzed at two different time-points after transplantation. Initially, both patients were still in remission, while disease progression had taken place at the time the second sample was collected. A total of 17 samples were analyzed, collected 3 to 65 months (median, 17 months) post-PBSCT.
All samples were enriched for CD19 ϩ cells. In parallel, PB samples of seven patients post-transplantation were sorted for the presence of the CD20 antigen. Patient characteristics are given in Table 1a and b. Each patient was diagnosed with MM based upon standard criteria.
14 The degree of plasma cell infiltration in the BM was determined by cytology. All patients had been included in a phase II study evaluating the efficacy of HDT with PBSCT for the treatment of MM 15 and they had given informed consent regarding collection of samples for this study.
Bone marrow (BM) samples obtained prior to mobilization therapy were used for identification of the tumorspecific CDR3 regions.
RNA and DNA isolation
Mononuclear cells (MNC) from bone marrow samples were obtained by Ficoll-Hypaque density centrifugation (Biochrom, Berlin, Germany). Total RNA was extracted using the method of Chomczynski and Sacchi 16 omitting the phenol extraction step and instead using the RNeasy columns (Qiagen, Hilden, Germany) for further purification. Genomic DNA was isolated by DNAzol (Gibco BRL, Eggenstein, Germany) providing the advantage of single tube isolation. DNA was precipitated with ethanol and redissolved in TE 10/1 (10 mm Tris-Cl pH 8.0, 1 mm EDTA).
Consensus PCR and sequencing of CDR3 PCR products
cDNA synthesis and consensus CDR3 PCR were essentially performed as previously described. 17, 18 Briefly, cDNA was synthesized using Oligo d(T) 16 and 2 g of total RNA from a BM sample taken prior to HDT. Reverse-transcription was performed with Moloney murine leukemia virus reverse transcriptase (Perkin Elmer, Weiterstadt, Germany) at 42°C for 15 min. The total cDNA assay was amplified using CDR3 consensus primers complementary to the V Hand J H -regions. 19 Primers were elongated at their 5Ј-ends to allow cloning into the pdirect vector (Clontech, Palo Alto, CA, USA). Additional sequences were as follows: 5Ј-ctcgctcgccca-3Ј and 3Ј-acccggcttggtc-5Ј. Cycling conditions were as follows: 40 cycles of denaturation for 1 min at 94°C, annealing for 1 min at 60°C, followed by extension for 1 min at 72°C. The last extension step was extended to 5 min.
Total PCR volumes were loaded on to low melting point agarose gels, the PCR products excised and the DNA recovered using the Easy Pure DNA Recovery System (Biozym, Göttingen, Germany). If the CDR3 PCR revealed a distinct clonal band, sequencing was carried out directly with the fmol sequencing kit (Promega, Heidelberg, Germany). Otherwise, the excised products were cloned using the PCR direct cloning system (Clontech). Plasmid-DNA was cyclesequenced after lysis of bacterial clones with 10 mm TrisCl pH 7.5, 1 mm EDTA and 100 g/ml of Proteinase K (Boehringer, Mannheim, Germany). Sequencing was done with the Sequitherm kit (Biozym) on an automated DNA sequencer (ALFexpress; Pharmacia, Freiburg, Germany). The tumor-specific CDR3 regions were identified by their predominant occurrence. ASO primers complementary to highly variable tumor-specific sequences were purchased commercially (MWG Biotech, Ebersberg, Germany). Their specificity was tested by amplifying DNA from a BM sample of the patient as positive control and buffy-coat DNA of healthy donors as negative control.
Immunofluorescence analysis
MNC from PB and BM were resuspended in 1 ϫ PBS to a concentration of 1.5-2 ϫ 10 10 /l. Fifty l cell suspension were incubated for 30 min at 4°C with the following antibodies: mouse IgG1 FITC isotype control and CD19 FITC (Immunotech, Hamburg, Germany).
The percentage of CD20 ϩ cells was determined with the anti-CD20 antibody IDEC-C2B8 which had been biotinylated for analytical purposes (kindly provided by Dr Moldenhauer, German Cancer Research Center, Heidelberg, Germany). Biotinylated antibody was detected using PElabelled streptavidin (kindly provided by Dr Moldenhauer). Both incubation steps were performed for 20 min at 4°C.
Immunofluorescence analysis was performed using a five-parameter FACSscan (Becton Dickinson, Heidelberg, Germany). In a live gate excluding debris, residual erythrocytes and neutrophils 50 000 cells were acquired. Blood levels of CD19 ϩ and CD19 Ϫ cells were calculated using the percentage of CD19 ϩ /CD19 Ϫ cells determined by flow cytometry times the absolute level of MNC. The numbers of MNC were derived from the differential white cell count less the number of neutrophils.
B-cell enrichment by preparative magnetic and fluorescence activated cell sorting
Total MNC of the PB were washed twice in PBS (Gibco BRL) containing 0.5% bovine serum albumin (BSA) and incubated with saturating concentrations of FITC-conjugated CD19 antibodies (Immunotech). In a first purification step, the CD19 ϩ B cells were enriched using the magnetic cell sorting system (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) consisting of the positive selection columns MS+ for MiniMACS and the CD19 MicroBeads. Purification was performed according to the manufacturer's protocol. In a second step, the CD19-FITC labelled B cells were preparatively sorted on a FACStar Plus (Becton Dickinson). The cell sorter was aligned and set up using MNC from healthy donors. Cells were analyzed after appropriate gating at a rate of 5000 cells per second. The CD19 ϩ subpopulations were sorted in the normal R mode with a sort rate of 20 cells per second upwards.
The CD20 ϩ cell fractions were obtained by double sorting with the MACS system. MNC were washed twice with PBS containing 0.5% BSA and 5% endobulin (Immuno GmbH, Heidelberg, Germany). Staining was done with the biotinylated anti-CD20 antibody (IDEC-C2B8) for 20 min at 4°C. After a single wash with PBS containing 0.5% BSA and 5% endobulin, cells were incubated for 20 min at 4°C with streptavidin-coupled MicroBeads (Miltenyi Biotec). Finally, CD20 ϩ cells were enriched using the positive selection columns MSϩ for MiniMACS. CD20
ϩ cells were subsequently loaded on a second MACS column. Purification was performed according to the manufacturer's protocol. All cell fractions were re-analyzed using a five parameter FACScan.
Proportion of clonotypic cells
Tumor cell contents in the CD19
ϩ /CD20 ϩ and in the CD19 Ϫ cell fractions were determined using a quantitative ASO PCR assay based on the method of limiting dilutions. The quantitative ASO PCR with DNA of the appropriate cell fractions was commenced with 0.06 g DNA (equivalent to 10 4 cells). If this initial PCR revealed a positive result, cell numbers were bisected consecutively until no more PCR signal was detectable. In the case of a negative initial PCR result, cell numbers were increased to 5 ϫ 10 5 cells. ASO PCR was performed at least twice at each dilution. PCR reactions were carried out in a total volume of 50 l with 2.5 U AmpliTaq Gold DNA-polymerase (Perkin Elmer), 2 mm MgCl 2 , 5 l GeneAmp 10 ϫ PCR buffer II, 0.2 mm of each dNTP and 0.6 m of each primer. Amplification conditions were as follows: after preheating at 94°C for 10 min, 10 initiating cycles comprising denaturation at 94°C for 30 s, annealing at 65°C for 30 s, and extension at 72°C for 1 min were carried out, followed by another 50 cycles with a lower annealing temperature of 60°C. The final extension was prolonged to 5 min. Aliquots of each reaction were analyzed on 5% NuSieve 3:1 agarose gels. Whether the isolated DNA could be amplified was tested with a primer pair complementary to the bcl-2 protooncogene sequence (Dianova, Hamburg, Germany). Each amplification experiment included a negative control without added DNA.
Tumor load was calculated on the basis that a single malignant cell in the reaction tube yields a positive PCR result. That the PCR assay used is sensitive enough to detect one cell in the PCR tube independent of the number of surrounding normal cells had been demonstrated by means of dilution series of the U266 myeloma cells in 500 000 melanoma cells (data previously shown). 20 Hence, the lowest dilution level with a positive PCR signal denoted the proportion of malignant cells in the sample. To further validate the PCR assay used, plasmids carrying the CDR3 regions of the tumor clone of three patients were diluted in 10-fold steps in placental DNA (Clontech) to simulate tumor loads from 0.1 down to 0.0001%. From these dilution series ASO PCR was performed as described above.
Statistical analysis
ϩ and CD19 Ϫ cell fraction were performed with the Mann-Whitney U test. For both statistical analyses the program Statistica for Windows (StatSoft, Tulsa, OK, USA) was used.
Results
Sequencing of CDR3 PCR products and ASO primers
The tumor-specific CDR3 region could be identified from all patients using the BM sample obtained at diagnosis or prior to mobilization therapy. For each patient, at least one ASO primer generating a PCR product of the expected size could be designed. The specificity of the created ASO primer could be demonstrated by not amplifying buffy-coat DNA from healthy donors.
Furthermore, dilution experiments with plasmid DNA carrying the CDR3 region of three different patients yielded positive PCR signals in all cases down to a dilution level of 0.0001%. These dilution experiments demonstrated the accuracy of the PCR assay with different ASO primers, and in addition they confirm the previously shown sensitivity of the PCR to detect a single copy of the myeloma CDR3 region in a PCR tube.
Immunophenotypic detection and cell sorting of B cells
The percentage of CD19 ϩ cells in PB samples of the eight patients prior to HDT and the data of the patients post-HDT are summarized in Tables 2 and 3 
. After VA[I]D treatment the percentages of CD19
ϩ cells in PB were in the range of 0.06 to 3.01% (median, 0.93%). PB samples of the 10 patients in remission post-HDT harbored a proportion of CD19 ϩ cells ranging from 1.77 to 40.18% (median, 6.56%), while in PB samples of the seven patients with progressive disease post-transplantation the median proportion of CD19 ϩ cells was 6.9% (range, 0.13-10.13%) ( Table 2 ). The proportion of CD20 ϩ cells in the PB samples of seven patients post-transplantation was a median of 10.8% (range, 2.4 to 45.5%) in complete accordance with the proportion of CD19 ϩ cells (Table 4 ). The coexpression pattern of both antigens confirmed their simultaneous pres- ence on the great majority of B cells, as already established. 6 After MACS-and FACS-sorting, the purities of the 25 enriched CD19
ϩ cell fractions were in the range of 81.3 to 99.8% (median, 97.1%) ( Table 2) Table 4) .
Determination of the proportion of tumor cells in CD19
ϩ
cell fractions
The results of the analysis of the proportion of tumor cells in the CD19 ϩ cell fractions are summarized in Table 2 and 1024 ϩ ; Mann-Whitney U test, P ϭ 0.05) ( Table 3 ). This increase in the number of CD19 ϩ tumor cells was particularly obvious in one patient, in whom samples in remission and during progression of the disease had been collected. The corresponding tumor cell numbers changed from not detectable to 222/ml. PCR results of the dilution series of CD19 ϩ cells of this patient are shown in Figure 3 .
Determination of the proportion of tumor cells in CD19
Ϫ
cell fractions
Results of the analysis of the proportion of tumor cells in the corresponding CD19 Ϫ cell fractions are summarized in Table 2 fractions clonotypic cells could be detected with a median number of 53 CD19
− tumor cells/ml (range, 0-678). In contrast to the CD19 ϩ compartment, this number was significantly lower in samples of patients in remission post-transplantation, in which tumor cells could be detected in only two out of 10 patients (median, 0; range, 0-54; P ϭ 0.006), indicating the efficacy of the high-dose regimen in almost completely eradicating the CD19 Ϫ tumor cells. However, as in the CD19 ϩ fractions, the tumor cell number rose again in the CD19 Ϫ cell fractions in patients with progressive disease after HDT with PBSCT (median, 63; range, 0-54177) (Table 3, Figure 3) .
Determination of the proportion of tumor cells in CD20 ϩ cell fractions
Results of the analysis of the proportion of tumor cells in the CD20
ϩ cell fractions are summarized in Table 4 . Numbers of tumor cells varied between 0 and 8.4 cells/ml PB (median, 2.7). This is in the same range as in the CD19 ϩ fractions (P ϭ 0.89).
Discussion
The lack of advance with conventional chemotherapies has promoted the use of high-dose regimens in the treatment of MM. Recent studies have demonstrated that five times higher CR rates were achieved using HDT with PBSCT compared to conventional treatment. 21 Nonetheless, most patients relapse, indicating survival of malignant cells with proliferative capacity.
This study was performed in order to quantitate the amounts of circulating clonotypic CD19 ϩ and CD19 Ϫ cells prior to and post-HDT with PBSCT and to consider both flow cytometry and molecular techniques as a measure of the tumor cell content in PB of patients with MM. A sequential analysis of whole PB mononuclear cell samples before and after PBSCT was performed by Billadeau et al 12 who showed that the tumor content in PB was independent of the disease stage, and that in most patients the number of malignant cells in PB was only minimally altered by intensive therapy including HDT with PBSCT. Using ASO PCR assays they determined tumor cell proportions ranging from below the detection level to 1.35%. These values are comparable to those obtained in our study with a range of below the detection level up to 0.3% (data not shown). The proportion of tumor cells in the CD19 ϩ fraction of PB was assessed by Chen and Epstein. 4 With a comparable method they detected a median of 0.5% clonal CD19 ϩ cells in PB. Our results indicate a lower percentage (median, 0.009%) of tumor cells in the CD19 ϩ cell fraction of patients in remission after VA[I]D treatment and after HDT. This might be due to the fact that in the study of Chen and Epstein, mainly newly diagnosed patients at an advanced disease stage (stage III in 3/4 patients), high tumor burden or active disease were assessed. The tumor cell proportion in both studies is, however, significantly lower than in the one published by Bergsagel et al. 7 Differences in the antigen profile detected by CD19 antibodies were supposed to account for the divergent results. Therefore, additional to the CD19 antibody we used the second pan-B cell marker CD20 to confirm the proportion of malignant CD19 ϩ B cells in the circulation of MM. We sorted B cells for the CD20 antigen and assessed tumor load in the CD20 ϩ fractions obtained. Comparable proportions of tumor cells in the CD20
ϩ as well as in the CD19 ϩ fractions verified the low amounts of tumor cells in the B cell compartment of peripheral blood of patients with MM.
Similar numbers of clonotypic CD19 ϩ cells after VA[I]D treatment and after HDT in patients in remission, and the increase of these CD19 ϩ cells with disease progression strongly suggest that these cells escape HDT regimens and are the source of relapse as already postulated for conventional treatment strategies. 11 The mature myeloma plasma cell has been described as a malignant population in PB. [22] [23] [24] In bone marrow, the myeloma plasma cells was characterized by the loss of CD19 expression. 25, 26 Recently, the existence of CD19 Ϫ circulating plasma cells was demonstrated by FACS analysis. 24 Our examinations also revealed the presence of clonotypic CD19
Ϫ cells, which might be the circulating malignant plasma cells. In contrast to the CD19 ϩ tumor cell fraction this tumor cell compartment was strongly affected by the HDT, as in patients in remission tumor cells could only be detected in two out of 10 CD19
Ϫ cell fractions. This would be in accordance with data from Pilarski et al 27 showing drug sensitivity of myeloma plasma cells in the bone marrow.
In conclusion, our results indicate that HDT could reduce the number of circulating tumor cells in the CD19
Ϫ compartment significantly, whereas the tumor load in the CD19 ϩ cell fraction was similar in patients in remission after conventional and after high-dose treatment suggesting a persistence of these cells despite intensified therapy. The increase in the number of tumor cells in both the CD19 ϩ and CD19
Ϫ subpopulations of PB substantiates the crucial role of the CD19 ϩ clonotypic cell in disease progression in patients with MM who have undergone HDT with PBSCT. To further determine the role of circulating clonotypic CD19 ϩ cells in this process, studies should be initiated especially of their proliferative capacity.
